Cambridge Epigenetix

6-base genome, multiomics, epigenetic sequencing

research tools

cambridge-epigenetix.com·Cambridge, United Kingdom·$88M total funding

01Overview 02People 03Projects 04Concepts 05Patents 06Public records 07Belief evolution

Plate C · C-Y9UA

Projects

5mC and 5hmC colorectal cancer cfDNA biomarker classifier

exploratory

biomarker · high · Thu Jan 01 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

Improve early-stage colorectal cancer detection using separate 5mC and 5hmC measurements in cell-free DNA liquid biopsy samples.

Analyzed cfDNA from treatment-naive CRC patients and healthy controls using duet evoC 6-base whole genome sequencing, then built CRC classifiers using differentially methylated regions.

2026 Communications Medicine publication reported classifier performance using 37 CRC patients and 32 healthy controls.

Models combining 5mC and 5hmC achieved AUC 0.95, outperforming modified cytosine-only models with AUC 0.66; findings support distinguishing 5mC and 5hmC to improve liquid biopsy sensitivity.

5-hydroxymethylcytosine cell-free DNA colorectal cancer biomarker

exploratory

biomarker · medium · Sat Jan 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

Detect colorectal cancer, including early-stage disease, using hydroxymethylation profiles in blood-derived cell-free DNA.

Created, tested, and validated a 5hmC-based classifier across more than two thousand blood samples; explored adding cfDNA fragment size and abundance features.

2022 Scientific Reports publication reported independent validation performance for CRC detection.

The classifier discriminated CRC from controls with AUC 90% and 55% sensitivity at 95% specificity; expanded features increased sensitivity to 63% at 95% specificity with AUC 91%.

duet multiomics solution evoC

undisclosed

platform · high

Resolve genetic and epigenetic DNA information from a single low-input sample by distinguishing 5-methylcytosine and 5-hydroxymethylcytosine alongside the four canonical DNA bases.

6-base whole-genome sequencing / multiomics assay that measures A, C, T, G, 5mC, and 5hmC from low-input DNA samples.

Platform described on biomodal site and used in published cfDNA colorectal cancer analysis.

The platform enabled separate measurement of 5mC and 5hmC in cfDNA and supported classifiers with improved diagnostic accuracy in colorectal cancer research.

Loading

Loading section...

0-100 chain-logic scale · 15 dimensions · scored on public evidence

Projects

5mC and 5hmC colorectal cancer cfDNA biomarker classifier

exploratory

biomarker · high · Thu Jan 01 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

Improve early-stage colorectal cancer detection using separate 5mC and 5hmC measurements in cell-free DNA liquid biopsy samples.

Analyzed cfDNA from treatment-naive CRC patients and healthy controls using duet evoC 6-base whole genome sequencing, then built CRC classifiers using differentially methylated regions.

2026 Communications Medicine publication reported classifier performance using 37 CRC patients and 32 healthy controls.

Models combining 5mC and 5hmC achieved AUC 0.95, outperforming modified cytosine-only models with AUC 0.66; findings support distinguishing 5mC and 5hmC to improve liquid biopsy sensitivity.

5-hydroxymethylcytosine cell-free DNA colorectal cancer biomarker

exploratory

biomarker · medium · Sat Jan 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

Detect colorectal cancer, including early-stage disease, using hydroxymethylation profiles in blood-derived cell-free DNA.

Created, tested, and validated a 5hmC-based classifier across more than two thousand blood samples; explored adding cfDNA fragment size and abundance features.

2022 Scientific Reports publication reported independent validation performance for CRC detection.

The classifier discriminated CRC from controls with AUC 90% and 55% sensitivity at 95% specificity; expanded features increased sensitivity to 63% at 95% specificity with AUC 91%.

duet multiomics solution evoC

undisclosed

platform · high

Resolve genetic and epigenetic DNA information from a single low-input sample by distinguishing 5-methylcytosine and 5-hydroxymethylcytosine alongside the four canonical DNA bases.

6-base whole-genome sequencing / multiomics assay that measures A, C, T, G, 5mC, and 5hmC from low-input DNA samples.

Platform described on biomodal site and used in published cfDNA colorectal cancer analysis.

The platform enabled separate measurement of 5mC and 5hmC in cfDNA and supported classifiers with improved diagnostic accuracy in colorectal cancer research.